Key Highlights
- 8.87% is the move in Evolent Health, Inc. (NYSE:EVH) in today's session on November 18, 2026, taking the traded price to USD 4.21 from a calculated prior close of USD 4.62, a calculated USD 0.41 drop.
- 1.10M shares traded in Evolent Health, Inc. today, after a 1.30% gap below the prior close at the open and a further 7.68% decline since the open, a calculated opening price near USD 4.56.
- 725.4 million is the third quarter 2026 Revenue in USD, up about 51% from USD 479.5 million, while the net loss narrowed to USD 23.6 million and adjusted EBITDA slipped to USD 34.3 million.
- 93.0% is the third quarter medical expense ratio, up from 85.0% a year earlier, with the adjusted EBITDA Margin falling to 4.7% from 8.1% as risk-based Performance Suite revenue reached USD 564.3 million.
What Moved Evolent Health, Inc. (NYSE:EVH) in Trading on November 18, 2026 (-USD 0.41, -8.87%)
The traded price of Evolent Health, Inc. (NYSE:EVH) in today's session on November 18, 2026 is USD 4.21, a move of -8.87% on Volume of 1.10M shares. On a calculated basis the prior close was USD 4.62 (USD 4.21 divided by 0.9113) and the USD move is -USD 0.41 (price minus prior close). The shares opened 1.30% below the prior close, a calculated USD 4.56, and traded 7.68% below the open. On a calculated basis, 113.1 million shares outstanding (117,535,151 Class A shares issued less 4,434,130 treasury shares) imply a market Capitalization near USD 476.2 million.
The Rationale: No Identified Catalyst After Margin Pressure for Evolent Health, Inc. (NYSE:EVH)
No catalyst for the November 18, 2026 move was identified in published coverage. The latest company event was the third quarter release on November 5, 2026. Revenue grew about 51%, but adjusted EBITDA fell to USD 34.3 million from USD 39.0 million and the medical expense ratio rose to 93.0% from 85.0%. The company reiterated 2026 revenue guidance of USD 2.6 billion to USD 2.7 billion and raised adjusted EBITDA guidance to USD 130.0 million to USD 135.0 million. Chief executive Seth Blackley said the AI platform and oncology solution will drive growth and margin expansion.
Valuation, Liquidity and Risks for Evolent Health, Inc. (NYSE:EVH)
The latest reported period is the third quarter ended September 30, 2026, filed November 5, 2026. Nine-month revenue was USD 1,874.1 million with a net loss attributable to common shareholders of USD 78.6 million, and the third quarter GAAP loss was USD 0.21 per share. Cash and cash equivalents were USD 148.3 million against long-term Debt of USD 969.5 million, so net debt is a calculated USD 821.2 million. The reserve for claims and performance-based arrangements rose to USD 376.1 million from USD 192.2 million at year end. Leverage, claims cost Volatility and a thin margin are the key risks.
Where Things Stand
Evolent Health, Inc. (NYSE:EVH) traded at USD 4.21 today, November 18, 2026, down 8.87% from a calculated prior close of USD 4.62, on volume of 1.10M shares. No catalyst was identified in published coverage. The latest reported quarter, ended September 30, 2026, showed revenue of USD 725.4 million, a net loss of USD 23.6 million, adjusted EBITDA of USD 34.3 million and cash of USD 148.3 million against USD 969.5 million of long-term debt. Medical costs, Leverage and thin margins remain the principal variables, moves of this size can reverse quickly, and this article is not Investment advice.






Please wait processing your request...